NPT 2042 for Epilepsy
Trial Summary
What is the purpose of this trial?
This study will compare the effect of NPT 2042 and placebo in subjects with GGE on the frequency and duration of electroencephalographic absence seizures, separated by a 14-day washout period. The study will be a single-center, double-blind, crossover study with subjects receiving either NPT 2042 80 mg BID orally or matching placebo BID in each of two treatment periods.
Eligibility Criteria
This trial is for people aged 16-75 with Genetic Generalized Epilepsy (GGE) and absence seizures. Participants must meet specific criteria, which are not detailed here.Inclusion Criteria
Exclusion Criteria
Timeline
Screening
Participants are screened for eligibility to participate in the trial
Treatment Period 1
Participants receive either NPT 2042 80 mg BID or matching placebo BID
Washout
A 14-day washout period between treatment periods
Treatment Period 2
Participants receive the alternate treatment (either NPT 2042 80 mg BID or matching placebo BID)
Follow-up
Participants are monitored for safety and effectiveness after treatment
Treatment Details
Interventions
- NPT 2042
- Placebo
Find a Clinic Near You
Who Is Running the Clinical Trial?
NeuroPro Therapeutics, Inc.
Lead Sponsor